Mandate

Vinge advises CELLINK in conjunction with the acquisition of Dispendix GmbH

November 30, 2018 M&A

Vinge has advised CELLINK AB, listed on First North Stockholm, in connection with the acquisition of all shares in Dispendix GmbH. Dispendix’s operations focus on bio dispensing technology and its patented technology emanates from a 10-year development within the German research institute Fraunhofer.

The acquisition strengthens CELLINK’s offering of complete 3D bioprint solutions. The purchase price amounts to MEUR 5 as well as the assumption of net debt in a maximum amount of MEUR 0.4. The purchase price is paid with MEUR 2 in cash and MEUR 3 with CELLINK class B shares (issue in kind to be resolved by CELLINK’s extraordinary general meeting during December 2018).

Vinge’s team primarily consisted of responsible partner Anders Strid, Daniel Lennartsson (M&A) and Alexander Lindeberg (IP). Noerr through, among others, responsible partner Dr. Holger Alfes, acted as local counsel in Germany.
 

Related

Vinge has advised HealthCap on the establishment of HealthCap IX

HealthCap IX has held its final closing, raising total commitments in excess of the target from a diverse investor base comprising established institutions, pension funds, and renowned investors within the life sciences sector. The strong support reflects continued confidence in HealthCap’s strategy and proven track record.
August 22, 2025

Vinge advises MAAG Gear with its MEUR 18.5 refinancing

Vinge has advised MAAG Gear in connection with entering into a EUR 18 500 000 facility agreement with Danske Bank A/S for the purpose of, among other things, refinancing its previous credit. MAAG Gear is a leading manufacturer of industrial gear solutions for cement and mining applications with a comprehensive product portfolio and global aftermarket services offering.
August 21, 2025

Vinge has advised Direktronik in conjunction with the acquisition of Qvintus

Direktronik, a subsidiary of Lagercrantz Group, has acquired all shares in Qvintus.
August 19, 2025